Spero Therapeutics Inc
SPRO2.420USD
+0.120+5.22%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
136.27M시가총액
손실P/E TTM
자세한 내용은 Spero Therapeutics Inc 회사
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc 정보
종목 코드 SPRO
회사 이름Spero Therapeutics Inc
상장일Nov 02, 2017
CEORajavelu (Esther)
직원 수32
유형Ordinary Share
회계 연도 종료Nov 02
주소675 Massachusetts Ave Ste 14
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02139-3309
전화18572421600
웹사이트https://sperotherapeutics.com/
종목 코드 SPRO
상장일Nov 02, 2017
CEORajavelu (Esther)
Spero Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-40270.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1695.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+20000.00%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-40270.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1695.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
사업별USD
이름
수익
비율
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
지역별USD
이름
수익
비율
United States
5.44M
100.00%
사업별
지역별
사업별USD
이름
수익
비율
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
주식 보유 통계
마지막 업데이트: Sat, Feb 7
마지막 업데이트: Sat, Feb 7
주주
주주 유형
주주
주주
비율
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
기타
70.37%
주주
주주
비율
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
기타
70.37%
주주 유형
주주
비율
Corporation
20.51%
Hedge Fund
6.27%
Investment Advisor
5.88%
Individual Investor
2.87%
Investment Advisor/Hedge Fund
2.52%
Venture Capital
1.64%
Research Firm
0.20%
Bank and Trust
0.02%
기타
60.09%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
108
9.24M
16.40%
-3.05M
2025Q3
106
9.05M
16.08%
-5.89M
2025Q2
114
26.06M
46.61%
-2.84M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
GSK plc
9.19M
16.31%
--
--
Mar 27, 2025
Pfizer Inc
2.36M
4.19%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.99M
3.53%
+39.47K
+2.02%
Sep 30, 2025
Anson Funds Management LP.
1.60M
2.85%
-11.90K
-0.74%
Sep 30, 2025
Renaissance Technologies LLC
1.45M
2.58%
+620.60K
+74.58%
Sep 30, 2025
Alphabet, Inc.
889.98K
1.58%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
527.48K
0.94%
+16.78K
+3.29%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
433.55K
0.77%
--
--
Sep 30, 2025
Rajavelu (Esther)
188.41K
0.33%
-40.27K
-17.61%
Nov 07, 2025
Mahadevia (Ankit)
364.22K
0.65%
-6.57K
-1.77%
Aug 28, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Invesco NASDAQ Future Gen 200 ETF
0.63%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
비율0.63%
Avantis US Small Cap Equity ETF
비율0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
